Table 2.
Characteristic | No. of trials | Hedges g (95% CI)* | Z score | Cochran Q† | p value‡ |
---|---|---|---|---|---|
Stereotyped behaviours | |||||
Drug intervention | |||||
SSRI | 7 | 0.25 (0.03 to 0.48) | 2.21§ | 0.55 | 0.005 |
Clomipramine (TCA) | 3 | 0.45 (−0.01 to 0.90) | 1.93 | ||
Age group | |||||
Children and adolescents | 8 | 0.21 (0.09 to 0.38) | 2.64§ | 1.94 | 0.001 |
Adults | 3 | 0.58 (0.11 to 1.04) | 2.29§ | ||
Global improvement | |||||
Drug intervention | |||||
SSRI | 5 | 1.04 (−0.04 to 2.12) | 1.90§ | 0.20 | 0.007 |
Clomipramine (TCA) | 3 | 1.45 (0.02 to 2.89) | 1.98§ | ||
Age group | |||||
Children and adolescents | 6 | 0.59 (−0.09 to 1.27) | 1.69 | 1.49 | 0.040 |
Adults | 3 | 2.41 (−0.44 to 5.25) | 1.66 |
CI = confidence interval; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
Random-effects model.
For heterogeneity assessment based on random-effects analysis.
Significance of the difference between effect sizes in the subgroups.
p < 0.05.